BioNotebook: Targacept, AcelRx/Grunenthal, Retrophin/Transcept, AmpliPhi
This article was originally published in Scrip
Targacept sinks on another failure; AcelRx signs EU Zalviso deal; Retrophin drops Transcept bid; and AmpliPhi nets $16.9m in stock sale.
You may also be interested in...
Emerging Company Profile: Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi has made progress in Phase I studies for its lead program. CEO Scott Salka explains to Mike Ward how he is looking to secure sufficient capital to support the Phase II development of AmpliPhi's lead program against chronic rhinosinusitis while advancing other product candidates.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.